Tinnitus Treatments Inspired by Neurodegenerative Therapies

Tinnitus, the perception of sound without an external source, affects millions and has long lacked a mechanism-based treatment. A new review by J.L. Liu and Peng Liu proposes that the answer may lie not in the ear, but in the brain, and specifically in processes shared with neurodegenerative diseases. Their analysis, published in *Frontiers in Aging Neuroscience*, systematically argues that tinnitus is a product of maladaptive neuroplasticity driven by mechanisms like neuroinflammation, synaptic dysfunction, and excitotoxicity—the same culprits implicated in conditions like Alzheimer’s and Parkinson’s disease.

A Shared Pathological Pathway in the Brain

The core argument by Liu and Liu is that chronic tinnitus is not merely a hearing problem but a brain network disorder. Their review synthesizes evidence showing that persistent tinnitus triggers and is maintained by maladaptive changes in both auditory and non-auditory brain regions. These changes mirror neurodegenerative processes. For instance, chronic neural hyperactivity in tinnitus may lead to excitotoxicity, where nerve cells are damaged or killed by excessive glutamate signaling. Similarly, neuroinflammation—the brain’s immune response—is observed in both tinnitus models and neurodegenerative conditions, disrupting normal neural communication and plasticity.

Three Promising Therapeutic Strategies from Neurology

The researchers systematically examined three main approaches borrowed from neurodegeneration research.

1. Calming Neuroinflammation

Drugs that suppress specific inflammatory pathways in the brain (like TNF-α or IL-1β inhibitors) have shown efficacy in animal models of tinnitus. By reducing this “brain inflammation,” these agents may help normalize the hyperactive neural circuits responsible for generating the phantom sound.

2. Modulating Neurotrophic Factors

Neurotrophic factors are proteins that support neuron survival and health. Their dysfunction is linked to neurodegeneration. In tinnitus, boosting factors like Brain-Derived Neurotrophic Factor (BDNF) could potentially repair maladaptive plasticity. Some experimental drugs aim to mimic or enhance these factors’ effects.

3. Blocking Excitotoxicity

Medications that protect neurons from excessive glutamate, such as certain NMDA receptor antagonists or memantine (used in Alzheimer’s disease), have been tested in tinnitus. The results are mixed but point to a viable mechanism. The challenge is to achieve therapeutic benefit without the side effects that have limited some of these drugs in neurology.

From Animal Models to Human Trials

Liu and Liu’s review highlights a critical gap: while preclinical data in animals is promising, human clinical trials are sparse and early-stage. Several drugs reviewed, including anti-inflammatories and neuroprotective agents, have progressed to early-phase trials for tinnitus, often demonstrating safety and hints of efficacy. However, large-scale, definitive Phase 3 trials are still needed. This translational lag is a major focus of their article. The repurposing strategy is advantageous because these compounds already have extensive safety data from other patient populations, potentially accelerating their path to approval for tinnitus.

This mechanistic approach also complements existing neuromodulation techniques, which aim to directly alter brain activity. As explored in our article on Neuromodulation Therapy for Tinnitus Relief, combining targeted brain stimulation with pharmacological neuroprotection could yield more potent and lasting effects.

Implications for Patients and Clinical Practice

For individuals with tinnitus, this research offers a new framework for understanding their condition—one that moves beyond the ear to encompass global brain health. It provides a strong scientific rationale for why tinnitus is often linked to stress, anxiety, and poor sleep, as these states profoundly influence neuroinflammation and neural plasticity. Our analysis of Tinnitus and Anxiety Research Trends and Insights details this complex relationship.

Practically, it means future treatments may come in the form of a pill that targets the brain’s immune response or protects synapses, rather than a device that masks sound. It also suggests that managing overall brain health through lifestyle could be a component of tinnitus management. Furthermore, this neurodegenerative link may explain comorbidities; the same processes that promote tinnitus could influence related sound tolerance conditions like hyperacusis or misophonia, which also involve central nervous system dysregulation.

A Framework for Future Research

The ultimate goal, as outlined by Liu and Liu, is to develop personalized, mechanism-based interventions. Not every tinnitus patient will have the same dominant pathology—some may have a strong neuroinflammatory component, while others may suffer primarily from synaptic dysfunction. Future research must work to identify biomarkers that can match a patient’s tinnitus subtype with the most appropriate repurposed drug. This precision medicine approach is the logical next step. The concept of borrowing from neurodegeneration is gaining traction, as also discussed in our piece on Tinnitus Treatments Inspired by Neurodegenerative Research.

By bridging auditory neuroscience and neurology, this review provides a coherent roadmap. It turns the persistent challenge of tinnitus treatment into an opportunity to apply decades of progress in brain disease therapeutics.

Source: Liu JL, Liu P. (2026). Repurposing Neurodegenerative Disease Therapeutic Strategies for Tinnitus Intervention: Mechanisms and Translational Potential. Front Aging Neurosci. DOI: 10.3389/fnagi.2026.1835649.